| |
| |
|
| Insider
Information: |
Torley Helen |
| Relationship: |
Director |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
683,004 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$31,666,361 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
683,004 |
|
|
| Total
Value |
$31,666,361 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -28.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
EVP, Chief Commercial ... |
2013-10-01 |
0 |
2011-08-29 |
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
|
2024-02-16 |
676,744 |
2014-09-16 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Quest Diagnostics Inc |
DGX |
Director |
2021-05-25 |
6,260 |
2018-05-15 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
169 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-02-22 |
4 |
D |
$48.69 |
$949,991 |
D/D |
(19,511) |
537,160 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
39,354 |
556,671 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-03-01 |
4 |
AS |
$45.58 |
$2,309,454 |
D/D |
(50,000) |
537,160 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-03-01 |
4 |
OE |
$14.66 |
$733,000 |
D/D |
50,000 |
587,160 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-05-11 |
4 |
AS |
$42.17 |
$2,151,099 |
D/D |
(50,000) |
537,160 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-05-11 |
4 |
OE |
$14.66 |
$733,000 |
D/D |
50,000 |
587,160 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-06-07 |
4 |
AS |
$39.66 |
$1,982,950 |
D/D |
(50,000) |
537,160 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-06-07 |
4 |
OE |
$14.66 |
$733,000 |
D/D |
50,000 |
587,160 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-07-06 |
4 |
AS |
$45.97 |
$2,298,650 |
D/D |
(50,000) |
537,160 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-07-06 |
4 |
OE |
$14.66 |
$733,000 |
D/D |
50,000 |
587,160 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-08-10 |
4 |
AS |
$40.42 |
$2,055,576 |
D/D |
(50,000) |
537,160 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-08-10 |
4 |
OE |
$14.66 |
$733,000 |
D/D |
50,000 |
587,160 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-09-07 |
4 |
AS |
$42.29 |
$2,118,846 |
D/D |
(50,000) |
537,160 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-09-07 |
4 |
OE |
$14.66 |
$733,000 |
D/D |
50,000 |
587,160 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-10-04 |
4 |
AS |
$39.97 |
$2,004,390 |
D/D |
(50,000) |
537,160 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-10-04 |
4 |
OE |
$14.66 |
$733,000 |
D/D |
50,000 |
587,160 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-11-08 |
4 |
AS |
$39.62 |
$1,990,768 |
D/D |
(50,000) |
537,160 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2021-11-08 |
4 |
OE |
$14.66 |
$733,000 |
D/D |
50,000 |
587,160 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,282 |
568,442 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2022-02-10 |
4 |
D |
$34.94 |
$579,934 |
D/D |
(16,598) |
551,844 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2022-02-12 |
4 |
D |
$34.20 |
$590,497 |
D/D |
(17,266) |
567,373 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2022-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,795 |
584,639 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2022-02-14 |
4 |
D |
$33.64 |
$508,805 |
D/D |
(15,125) |
580,977 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2022-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,729 |
596,102 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2022-02-15 |
4 |
D |
$34.43 |
$237,292 |
D/D |
(6,892) |
587,177 |
0 |
- |
|
169 Records found
|
|
Page 3 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
